• Onco-Innovations reported interim preclinical microsome metabolism results for ONC010’s API, A83B4C63, across human, rat, dog systems.
• Results have already been presented as interim findings; additional metabolite characterization is planned, with hepatocyte study results pending.
• A83B4C63 showed metabolism in all species; rates differed by species, with pathways consistent with cytochrome P450 activity.
• Program did not flag issues expected to block continuation of ONC010’s planned preclinical development toward future dosing and regulatory planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202609091800TNWSWRCACNPR_____1AdyFY2X4) on September 09, 2026, and is solely responsible for the information contained therein.